| Literature DB >> 33862068 |
Andreas Willerslev-Olsen1, Lise Mette Rahbek Gjerdrum2, Lise M Lindahl3, Terkild B Buus1, Emil M H Pallesen1, Maria Gluud1, Michael Bzorek4, Boye S Nielsen5, Maria R Kamstrup6, Anne Hald Rittig3, Charlotte M Bonefeld1, Thorbjørn Krejsgaard1, Carsten Geisler1, Sergei B Koralov7, Thomas Litman1, Jurgen C Becker8, Anders Woetmann1, Lars Iversen3, Niels Odum9.
Abstract
Staphylococcal enterotoxins are believed to fuel disease activity in cutaneous T-cell lymphoma. Recent data support this by showing that antibiotics inhibit malignant T cells in skin lesions in mycosis fungoides and Sézary syndrome, the most common forms of cutaneous T-cell lymphoma. Yet, it remains incompletely characterized how staphylococcal enterotoxins fuel disease activity. In this study, we show that staphylococcal enterotoxins induce the expression of the oncogenic microRNA miR-155 in primary malignant T cells. Thus, staphylococcal enterotoxins and Staphyloccocus aureus isolates from lesional skin of patients induce miR-155 expression at least partly through the IL-2Rg‒Jak‒signal transducer and activator of transcription 5 pathway, and the effect is augmented by the presence of nonmalignant T cells. Importantly, mycosis fungoides lesions harbor S. aureus, express Y-phosphorylated signal transducer and activator of transcription 5, and display enhanced miR-155 expression, when compared with nonlesional and healthy skin. Preliminary data show that aggressive antibiotic therapy is associated with decreased Y-phosphorylated signal transducer and activator of transcription 5 and miR-155 expression in lesional skin in two patients with Sézary syndrome. In conclusion, we show that S. aureus and its enterotoxins induce enhanced expression of oncogenic miR-155, providing mechanistic insight into the role of S. aureus in cutaneous T-cell lymphoma. Our findings support that environmental stimuli such as bacteria can fuel disease progression in cutaneous T-cell lymphoma.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33862068 DOI: 10.1016/j.jid.2021.01.038
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551